Physician

Michael Charles Marte, M.D.

According to 2025 Medicare claims, Michael Marte, M.D. (NPI: 1518058502) practices hematology/oncology in the Wilmington, NC market, with the plurality of this provider's patient population coming from New Hanover, NC. This provider's primary affiliated billing organization is WILMINGTON HEALTH PLLC (NPI: 1881632339; TIN: 561980160) and primary practice location at 28401-7684. Marte is affiliated with the Mission Health Partners, LLC (ACO ID: A2591), CoreHealth Alliance LLC (ACO ID: A5645), and Physicians Healthcare Collaborative (ACO ID: D0068), participating under both the MSSP and REACH models.

Marte's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 502 traditional Medicare patients, billed 175,633 HCPCS/CPT codes, and received $3,402,038 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,002 prescription claims across 183 beneficiaries totaling $2,940,567 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 33 claims. Open Payments data shows 70 records totaling $1,405. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $74,918 to $3,402,038. Similarly, Part D prescription costs have moved sharply higher in recent years, from $617,378 to $2,940,567. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,871 to $218.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	343	988	$74,918
2016	349	915	$67,309
2017	443	10,983	$137,175
2018	573	106,605	$1,191,298
2019	560	106,191	$984,843
2020	468	308,817	$2,930,075
2021	503	325,405	$2,301,344
2022	616	352,111	$2,529,891
2023	616	290,633	$2,533,474
2024	502	175,633	$3,402,038

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	125	581	$617,378
2016	136	579	$820,121
2017	165	636	$877,397
2018	123	430	$896,124
2019	99	361	$776,332
2020	112	544	$915,045
2021	150	695	$2,089,180
2022	217	906	$2,667,087
2023	212	959	$2,500,604
2024	183	1,002	$2,940,567

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	156	$8,735
2016	24	158	$7,093
2017	N/R	82	$1,433
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	26	$487
2022	N/R	12	$201
2023	N/R	N/R	N/R
2024	N/R	33	$826

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	304	552	$86
82728	Ferritin (blood protein) level	125	215	$13
80053	Blood test, comprehensive group of blood chemicals	272	1,333	$10
36415	Insertion of needle into vein for collection of blood sample	402	1,750	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	394	1,767	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	57	1,435	$749,472
Revlimid	Lenalidomide	44	1,085	$659,016
Brukinsa	Zanubrutinib	20	600	$298,670
Imbruvica	Ibrutinib	13	364	$241,433
Nubeqa	Darolutamide	12	360	$164,731

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8530	Cyclophosphamide; oral, 25 mg	N	N/R	21	$676
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	70	$1,405	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael Charles Marte, M.D.?

Tedicare shows public-source Medicare data for Michael Charles Marte, M.D. (NPI 1518058502), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Charles Marte, M.D. have ACO affiliation data?

Michael Charles Marte, M.D. is shown with ACO affiliation data for Mission Health Partners, LLC (MSSP, ACO ID A2591), CoreHealth Alliance LLC (MSSP, ACO ID A5645), and Physicians Healthcare Collaborative (REACH, ACO ID D0068).

What billing organization is linked to Michael Charles Marte, M.D.?

Michael Charles Marte, M.D. is linked to WILMINGTON HEALTH PLLC (billing NPI 1881632339) in the available physician profile data.

Does Michael Charles Marte, M.D. have Open Payments data?

Michael Charles Marte, M.D. has 70 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.